Brean Capital’s healthcare analyst Difei Yang weighed in this morning with a few insights on Zogenix (NASDAQ:ZGNX), after the healthcare research firm Symphony Health Solutions …
In a research report released Monday, Brean Capital analyst Difei Yang maintained a Buy rating on Zogenix (NASDAQ:ZGNX) with a $2.50 price target, …
In a research report sent to investors today, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics (NASDAQ:OSIR) with a …
Before the market opened Tuesday, Brean Capital analyst Difei Yang maintained a Buy rating on Zogenix (NASDAQ:ZGNX) with a price target of $2.50, …
In a research report released today, Brean Capital analyst Difei Yang reiterated a Buy rating on Horizon Pharma (NASDAQ:HZNP) with a price target …
Brean Capital analyst Difei Yang initiated coverage on shares of Horizon Pharma (NASDAQ:HZNP) with a Buy rating and a price target of $18, which represents a …
